Valsartan Recall in US – Opportunity Coming To End
Post the recall of Valsartan formulations (generics of Diovan) by various generics in the US, a shortage was created resulting in significant price...
495 Views
Para IV Winners and Losers - August 2018
This month’s Para IV developments suggest that there is likely to be benefit to Mylan Nv (MYL US) for Minivelle, Teva Pharmaceutical Sp Adr (TEVA...
278 Views
Para IV Winners and Losers - April 2018
This month’s Para IV developments suggest that there is likely to be benefit to Cipla Ltd (CIPLA IN) on Xopenex HFA, Alvogen, Teva Pharmaceutical...
161 Views
Biosimilar Battlefield: An Update
Korea's biosimilar plays, Celltrion Inc (068270 KS) , Celltrion Pharm Inc (068760 KS) , Celltrion Healthcare (091990 KS) , and Samsung Biologics...
426 Views
Biosimilar Battlefield: Celltrion Forecasts
This Insight uses the biosimilar market model discussed in Surveying The Biosimilar Battlefield to build a long-term revenue forecast for the...
478 Views